Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-12 |
2024-06 |
-0.14 |
N/A |
N/A |
N/A |
2024-05-15 |
2024-03 |
0 |
-0.46 |
N/A |
N/A |
2024-03-11 |
2023-12 |
-1.68 |
-0.71 |
0.97 |
57.74% |
2023-11-14 |
2023-09 |
-1.88 |
-1.23 |
0.65 |
34.57% |
2023-08-14 |
2023-06 |
-2.07 |
-2 |
0.07 |
3.38% |
2023-05-12 |
2023-03 |
-2.85 |
-2.06 |
0.79 |
27.72% |
Date |
Firm |
Action |
From |
To |
2023-08-23 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-14 |
BTIG |
Upgrade |
Buy |
Buy |
2023-06-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-15 |
BTIG |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-12-13 |
ACHENBACH BRIAN |
Officer |
144.73K |
Sale |
2023-07-04 |
CHILL ADAM J |
Director |
19.17K |
Stock Award(Grant) |
2024-01-01 |
FORTRESS BIOTECH, INC. |
Beneficial Owner of more than 10% of a Class of Security |
1.93M |
Stock Award(Grant) |
2023-07-04 |
HERSKOWITZ NEIL |
Director |
19.70K |
Stock Award(Grant) |
2023-04-23 |
LITCHMAN MANUEL |
Chief Executive Officer |
111.08K |
Stock Award(Grant) |
2021-08-30 |
ROSENWALD LINDSAY A |
Director |
218.42K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
177.58K |
1.10M |
2.41% |
2023-06-29 |
Blackrock Inc. |
101.57K |
630.74K |
1.38% |
2023-09-29 |
Koss-olinger Consulting, Llc |
100.00K |
207.00K |
1.36% |
2023-06-29 |
Laurion Capital Management, LP |
51.01K |
316.75K |
0.69% |
2023-06-29 |
Geode Capital Management, LLC |
49.76K |
309.02K |
0.68% |
2023-06-29 |
Renaissance Technologies, LLC |
44.39K |
275.66K |
0.60% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
104.17K |
646.88K |
1.42% |
2023-06-29 |
Vanguard Extended Market Index Fund |
71.43K |
443.61K |
0.97% |
2023-05-30 |
Fidelity Extended Market Index Fund |
23.07K |
147.44K |
0.31% |
2023-07-30 |
DFA U.S. Small Cap Series |
14.36K |
74.66K |
0.20% |
2023-08-30 |
iShares Micro Cap ETF |
12.43K |
39.41K |
0.17% |
2023-06-29 |
Delaware Group Equity Fds IV-Delaware Healthcare Fund |
8.00K |
49.68K |
0.11% |
Split |
Date |
1 : 15 |
2023-04-04 |